Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Rajesh, Kaldate"'
1
Akademický článek
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
Autor: Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis,
Externí odkaz: https://doaj.org/article/08953196fa7443bbb663ea7061737037
Zobrazit plný text záznamu
6
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
Autor: Rajesh Kaldate, Eric Jonasch, Robert J. Motzer, Bernard Escudier, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, E. Wang, Toni K. Choueiri, Daniel J. George, Dana T. Aftab, Christian Scheffold, Nizar M. Tannir
Publikováno v: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis, plasma b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe64a74272813e5022c59143c92cf97b
https://doi.org/10.1186/s12885-021-08630-w
Zobrazit plný text záznamu
7
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Autor: David W. Markby, Rajesh Kaldate, Robin Kate Kelley, Joong-Won Park, Ghassan K. Abou-Alfa, Vincent C. Tam, Anthony B. El-Khoueiry, Philippe Merle, Thomas Yau, Stephen L. Chan, Ann-Lii Cheng, Lorenza Rimassa, Vincenzo Dadduzio, Jean-Frédéric Blanc, Tim Meyer, Albert Tran
Publikováno v: Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Purpose: The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f32f4cbf17e7c45537bb599d64fd94
https://pubmed.ncbi.nlm.nih.gov/32636319
Zobrazit plný text záznamu
9
Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
Autor: Vincenzo Dadduzio, David W. Markby, Joong-Won Park, Suvajit Sen, Thomas Yau, Ghassan K. Abou-Alfa, Lorenza Rimassa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Stephen L. Chan, Rajesh Kaldate, Jean-Frédéric Blanc, Baek-Yeol Ryoo, Robin Kate Kelley, Tim Meyer
Publikováno v: Journal of Clinical Oncology. 37:423-423
423 Background: AFP response, defined as a decrease in serum levels of the tumor marker AFP after therapy, may be associated with improved survival of patients (pts) with HCC treated with locoregional or systemic therapy, and high baseline AFP levels
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da877d5e656a0db4c71c57e1bc1c57e2
https://doi.org/10.1200/jco.2019.37.4_suppl.423
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje